IGF-1 LR3 injection is administered subcutaneously or intramuscularly, mainly used to promote muscle growth, accelerate tissue repair, improve metabolic function, and anti-aging. Its mechanism of action is similar to natural IGF-1, but its more long-lasting effects give it unique advantages in clinical and exercise science. It activates the downstream PI3K/Akt/mTOR signaling pathway by binding to the IGF-1 receptor (IGF1R) on the cell surface. This pathway is the core regulatory network for cell growth, proliferation, and metabolism, promoting the translocation of glucose transporter 4 (GLUT4) to the cell membrane and enhancing glucose uptake and utilization; Simultaneously inhibiting gluconeogenesis and lowering blood sugar levels. It also directly stimulates protein synthesis, inhibits protein breakdown, and promotes muscle cell hypertrophy and proliferation. By upregulating Cyclin D1 and downregulating Cyclin p21, cell division and regeneration are accelerated.
|
|
|
IGF 1 LR3 COA
The paradox of IGF-1 LR3 in Aβ plaque remodeling and cognitive improvement in Alzheimer's disease
Alzheimer's disease (AD) is the most common neurodegenerative disease, characterized by senile plaques formed by the deposition of beta amyloid protein (A β), neurofibrillary tangles (NFTs) formed by excessive phosphorylation of Tau protein, and neuronal loss. In recent years, the role of the insulin-like growth factor (IGF) system in the pathophysiology of Alzheimer's disease has received increasing attention. Among them, IGF 1 LR3 Injection, as a molecular modified IGF-1 analog, has become a hot topic in AD treatment research due to its long half-life and enhanced biological activity.
Aβ plaque remodeling: evidence and mechanism
One of the most significant effects of IGF 1 LR3 Injection in AD treatment is its regulatory role in A β pathology, particularly in promoting A β plaque remodeling and clearance. This section will explore in detail the experimental evidence and molecular mechanisms by which IGF-1 LR3 affects A β metabolism.
Research has shown that IGF-1 LR3 treatment can significantly alter the composition and morphology of A β plaques. Engel et al. found that 5XFAD mice treated with intranasal LR3-IGF-1 for 7 months exhibited a decrease in fibrous plaques and an increase in inert plaques in their cortical regions. The transformation of this type of plaque is of great significance, as fibrous plaques are typically associated with stronger neurotoxicity and inflammatory responses, while inert plaques are relatively benign.
More importantly, LR3 treatment is accompanied by a reduction in low molecular weight A β oligomers. A β oligomers are currently considered the main neurotoxic substances in AD, with stronger toxicity than fibrous A β and closely related to synaptic dysfunction and cognitive impairment. Therefore, reducing A β oligomers may be one of the key benefits of IGF-1 LR3 therapy.
A β clearance mechanism
The mechanism by which IGF-1 LR3 promotes A β clearance involves multiple pathways, including enhancing cell phagocytosis, promoting enzyme degradation, and improving vascular clearance:
Glial cell-mediated phagocytosis
Research has found that IGF-1 LR3 can enhance the phagocytic ability of microglia and astrocytes towards A β. In vitro experiments showed that LR3-IGF-1 treatment can enhance the uptake of A β 1-42 peptide by BV-2 microglia, which is associated with upregulation of gene pathways related to actin remodeling and endocytosis. Meanwhile, studies have shown that the absence of the scaffold protein Rack1 in microglia increases IGF-1 levels, which in turn enhances the phagocytic ability of astrocytes through IGF-1-IGF-1R signaling and reduces A β deposition.
Enzyme degradation pathway
IGF-1 signaling may upregulate the expression of various A β - degrading enzymes, including insulin-dependent enzyme (IDE), enkephalinase (NEP), and matrix metalloproteinases (MMPs). These enzymes can degrade A β into smaller, non-toxic fragments, thereby reducing A β deposition.
Vascular clearance and blood-brain barrier function
IGF-1 is believed to improve blood-brain barrier function and promote the clearance of A β from interstitial fluid to peripheral blood. This process involves upregulating the expression of A β transporters such as low-density lipoprotein receptor associated protein 1 (LRP-1) and P-glycoprotein. However, studies have shown that elevated peripheral IGF-1 has not been confirmed to have an effect on A β clearance in all models, suggesting that the role of IGF-1 in A β vascular clearance may depend on specific physiological environments and administration methods.
Regulation of neuroinflammation
The deposition of A β usually triggers neuroinflammatory reactions, activating microglia and astrocytes to release pro-inflammatory cytokines, exacerbating neuronal damage. IGF-1 LR3 exhibits a regulatory effect on neuroinflammation, possibly by inhibiting the NF - κ B signaling pathway and reducing the production of pro-inflammatory cytokines such as TNF - α, IL-1 β, and IL-6 to alleviate the inflammatory response.
Regulatory effect and evidence of IGF-1 LR3 on A β pathology
| Regulatory Mechanism | Experimental Evidence | Model System |
| Transformation of plaque morphology | Fibrous plaques decrease, inert plaques increase | 5XFAD transgenic mice |
| Reduction of A β oligomers | Reduced levels of low molecular weight A β oligomers | 5XFAD transgenic mice |
| Phagocytosis of microglia | Enhance the uptake of A β 1-42 peptide | BV-2 microglia |
| Phagocytosis of astrocytes | Enhanced phagocytic activity mediated by IGF-1 | Primary astrocytes |
| Neuroinflammatory regulation | Reduced release of pro-inflammatory cytokines | Multiple AD models |
Regional Specific Effects
Interestingly, the impact of IGF-1 LR3 on A β pathology exhibits brain region specificity. Research has shown that LR3 treatment mainly observed improvement in A β plaques in the cerebral cortex, while the effect was not as significant in the hippocampus. This regional difference may be related to differences in IGF-1R expression levels, glial cell density, or A β deposition characteristics in different brain regions.
The lack of improvement in A β pathology in the hippocampus, a key brain region for learning and memory, may partially explain why IGF-1 LR3 treatment did not produce significant cognitive benefits while improving overall A β load. This finding suggests that successful AD treatment may require ensuring sufficient pathological improvement in key memory related brain regions.
Experimental Evidence
Multiple studies have confirmed the lack of cognitive improvement in IGF 1 LR3 Injection therapy. Engel et al. treated 5XFAD mice with intranasal LR3-IGF-1 for 7 months and evaluated their cognitive function through multiple behavioral tests, including Morris water maze and new object recognition. They found that although cortical A β pathology improved, the treatment did not significantly alter cognitive symptoms. Similarly, in human clinical trials, chronic elevation of plasma IGF-1 levels did not show cognitive benefits for AD patients in a one-year growth hormone secretagogue trial. This paradox is not unique to IGF-1 LR3, and similar phenomena have been observed in other A β targeted therapies, such as some A β antibody therapies that can effectively clear A β from the brain but have limited cognitive benefits. This indicates that there may be significant gaps in the current understanding of the pathological mechanisms of AD.
Potential Explanation of Paradox
Pathological complexity and irreversibility
AD is a complex multi pathological process disease that includes not only A β deposition, but also various pathological features such as Tau protein lesions, neuroinflammation, synaptic dysfunction, and neuronal loss. In the late stage of the disease, these pathological changes may have reached an irreversible point, and even if A β deposition is cleared, other pathological processes will still drive disease progression and cognitive decline.
Especially neuronal loss, which is an important structural basis for cognitive impairment in AD patients. At the beginning of IGF-1 LR3 treatment, significant neuronal loss may have occurred, and simple clearance of A β cannot restore the lost neurons and neural network connections.
Treatment Time Window Issue
More and more evidence suggests that A β targeted therapy may have a critical treatment time window. In the early stages of the disease, intervention may be more effective when A β pathology already exists but other downstream pathological processes have not yet fully unfolded. In the late stage of the disease, when the pathological cascade reaction has been fully initiated, simple clearance of A β may no longer be sufficient to alter the disease progression.In most preclinical studies, IGF-1 LR3 treatment begins after A β deposition has been established, which may miss the optimal treatment window. Future research needs to explore the effectiveness of interventions at earlier stages of the disease.
Neural circuits and synaptic plasticity disorders
Long term exposure to A β oligomers may lead to persistent changes in synaptic plasticity and dysfunction of neural circuits, even if A β is cleared, these functional changes may still persist. A β oligomers are known to impair long-term potentiation (LTP), promote long-term depression (LTD), and affect neurotransmitter receptor traffic and stability.In addition, studies have found that although IGF-1 LR3 therapy can reduce low molecular weight A β oligomers, it may have limited effects on other toxic A β species (such as A β * 56 or higher molecular weight oligomers), which may continue to impair synaptic function.
Hot Tags: igf 1 lr3 injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale